GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
GW Pharmaceuticals will report its financial results for Q3 2020 on November 3, 2020, with a conference call scheduled for 8:30 a.m. EST. The company focuses on developing cannabinoid-based therapeutics, notably EPIDIOLEX® for severe epilepsy syndromes. This product is approved in the U.S. and EU for certain seizure disorders. GW is advancing multiple clinical programs, including a Phase 3 trial in Rett syndrome, and aims for FDA approval of various other cannabinoid candidates.
- Strengthening product pipeline with Phase 3 trial in Rett syndrome.
- EPIDIOLEX® approved for Lennox-Gastaut syndrome and Dravet syndrome in the U.S. and EU.
- None.
LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will also host a conference call the same day at 8:30 a.m. EST. Conference call information will be provided in the financial results press release and on the Company website (www.gwpharm.com) in the investor section. A replay of the call will also be available through the Company's website shortly after the call.
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company is also carrying out a Phase 3 trial in Rett syndrome and has a deep pipeline of additional cannabinoid product candidates, including nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |
FAQ
When will GW Pharmaceuticals announce its Q3 2020 financial results?
What is EPIDIOLEX® used for?
What clinical trials is GW Pharmaceuticals conducting?
